\begin{tabular}{llll}
Rank & Pair & Description & NN \\
\hline
\bfseries 1 & \bfseries D00438 & \bfseries Nimodipine & 0.750 \\
\bfseries\indb{D,K}   & \bfseries hsa779 & \bfseries CACNA1S: calcium channel,&\\
     &&\bfseries voltage-dependent, L type, alpha 1S subunit & 0.578 \\
\hline
 2 &  D00726 &  Metoclopramide & 0.200 \\
   &  hsa1138 &  CHRNA5: cholinergic receptor,&\\
     && nicotinic, alpha 5 & 0.443 \\
\hline
\bfseries 3 & \bfseries D03365 & \bfseries Nicotine & 0.409 \\
\bfseries\indb{C,D}   & \bfseries hsa1137 & \bfseries CHRNA4: cholinergic receptor,&\\
     &&\bfseries nicotinic, alpha 4 & 0.528 \\
\hline
 4 &  D02098 &  Proparacaine hydrochloride & 0.667 \\
   &  hsa8645 &  KCNK5: potassium channel,&\\
     && subfamily K, member 5 & 0.013 \\
\hline
\bfseries 5 & \bfseries D00552 & \bfseries Benzocaine & 0.579 \\
\bfseries\indb{K}   & \bfseries hsa6331 & \bfseries SCN5A: sodium channel, voltage-gated,&\\
     &&\bfseries type V, alpha subunit & 0.604 \\
\hline
 6 &  D00775 &  Riluzole & 0.000 \\
   &  hsa2898 &  GRIK2: glutamate receptor,&\\
     && ionotropic, kainate 2 & 0.811 \\
\hline
 7 &  D00294 &  Diazoxide & 0.175 \\
   &  hsa10060 &  ABCC9: ATP-binding cassette,&\\
     && sub-family C (CFTR/MRP), member 9 & 0.682 \\
\hline
 8 &  D00477 &  Procainamide hydrochloride & 0.714 \\
   &  hsa6336 &  SCN10A: sodium channel, voltage-gated,&\\
     && type X, alpha subunit & 0.604 \\
\hline
 9 &  D00640 &  Propafenone hydrochloride & 0.457 \\
   &  hsa6336 &  SCN10A: sodium channel, voltage-gated,&\\
     && type X, alpha subunit & 0.604 \\
\hline
 10 &  D00524 &  Carbachol & 0.350 \\
   &  hsa1134 &  CHRNA1: cholinergic receptor,&\\
     && nicotinic, alpha 1 (muscle) & 0.460 \\
\hline
\bfseries 11 & \bfseries D00538 & \bfseries Zonisamide & 0.364 \\
\bfseries\indb{D,K}   & \bfseries hsa6331 & \bfseries SCN5A: sodium channel, voltage-gated,&\\
     &&\bfseries type V, alpha subunit & 0.604 \\
\hline
\bfseries 12 & \bfseries D01969 & \bfseries Gallopamil hydrochloride & 0.865 \\
\bfseries\indb{K}   & \bfseries hsa778 & \bfseries CACNA1F: calcium channel,&\\
     &&\bfseries voltage-dependent, L type, alpha 1F subunit & 0.561 \\
\hline
 13 &  D00547 &  Sevoflurane & 0.042 \\
   &  hsa2570 &  GABRR2 & 0.683 \\
\hline
 14 &  D00349 &  Isradipine & 0.733 \\
   &  hsa773 &  CACNA1A: calcium channel,&\\
     && voltage-dependent, P/Q type, alpha 1A subunit & 0.285 \\
\hline
 15 &  D00524 &  Carbachol & 0.350 \\
   &  hsa1139 &  CHRNA7: cholinergic receptor,&\\
     && nicotinic, alpha 7 & 0.356 \\
\hline
\bfseries 16 & \bfseries D03830 & \bfseries Diltiazem malate & 0.358 \\
\bfseries\indb{K}   & \bfseries hsa776 & \bfseries CACNA1D: calcium channel,&\\
     &&\bfseries voltage-dependent, L type, alpha 1D subunit & 0.641 \\
\hline
 17 &  D00799 &  Trifluoperazine hydrochloride & 0.879 \\
   &  hsa3782 &  KCNN3: potassium intermediate/small&\\
     && conductance calcium-activated channel, subfamily N, member 3 & 0.630 \\
\hline
\bfseries 18 & \bfseries D00616 & \bfseries Diltiazem hydrochloride & 0.404 \\
\bfseries\indb{K}   & \bfseries hsa776 & \bfseries CACNA1D: calcium channel,&\\
     &&\bfseries voltage-dependent, L type, alpha 1D subunit & 0.641 \\
\hline
 19 &  D00136 &  Haloperidol & 0.303 \\
   &  hsa116443 &  GRIN3A: glutamate receptor,&\\
     && ionotropic, N-methyl-D-aspartate 3A & 0.443 \\
\hline
\bfseries 20 & \bfseries D00283 & \bfseries Clozapine & 0.371 \\
\bfseries\indb{C}   & \bfseries hsa170572 & \bfseries HTR3C & 0.738 \\
\hline
 21 &  D00549 &  Propofol & 0.207 \\
   &  hsa8001 &  GLRA3 & 0.833 \\
\hline
 22 &  D00639 &  Mexiletine hydrochloride & 0.524 \\
   &  hsa6336 &  SCN10A: sodium channel, voltage-gated,&\\
     && type X, alpha subunit & 0.604 \\
\hline
 23 &  D00477 &  Procainamide hydrochloride & 0.714 \\
   &  hsa8645 &  KCNK5: potassium channel,&\\
     && subfamily K, member 5 & 0.013 \\
\hline
 24 &  D00499 &  Pentobarbital & 0.161 \\
   &  hsa1134 &  CHRNA1: cholinergic receptor,&\\
     && nicotinic, alpha 1 (muscle) & 0.460 \\
\hline
 25 &  D00293 &  Diazepam & 0.355 \\
   &  hsa8001 &  GLRA3 & 0.833 \\
\hline
\bfseries 26 & \bfseries D00451 & \bfseries Sumatriptan & 0.280 \\
\bfseries\indb{C}   & \bfseries hsa170572 & \bfseries HTR3C & 0.738 \\
\hline
 27 &  D00495 &  Paramethadione & 0.750 \\
   &  hsa8913 &  CACNA1G: calcium channel,&\\
     && voltage-dependent, T type, alpha 1G subunit & 0.448 \\
\hline
 28 &  D00513 &  Pindolol & 0.273 \\
   &  hsa170572 &  HTR3C & 0.738 \\
\hline
 29 &  D00438 &  Nimodipine & 0.750 \\
   &  hsa781 &  CACNA2D1: calcium channel,&\\
     && voltage-dependent, alpha 2/delta subunit 1 & 0.194 \\
\hline
 30 &  D00545 &  Isoflurane & 0.571 \\
   &  hsa2742 &  GLRA2: glycine receptor, alpha 2 & 0.769 \\
\hline
\bfseries 31 & \bfseries D00619 & \bfseries Verapamil hydrochloride & 0.971 \\
\bfseries\indb{D,K}   & \bfseries hsa778 & \bfseries CACNA1F: calcium channel,&\\
     &&\bfseries voltage-dependent, L type, alpha 1F subunit & 0.561 \\
\hline
 32 &  D00524 &  Carbachol & 0.350 \\
   &  hsa1138 &  CHRNA5: cholinergic receptor,&\\
     && nicotinic, alpha 5 & 0.443 \\
\hline
\bfseries 33 & \bfseries D03365 & \bfseries Nicotine & 0.409 \\
\bfseries\indb{C}   & \bfseries hsa1134 & \bfseries CHRNA1: cholinergic receptor,&\\
     &&\bfseries nicotinic, alpha 1 (muscle) & 0.460 \\
\hline
 34 &  D02088 &  Tocainide hydrochloride & 0.684 \\
   &  hsa6336 &  SCN10A: sodium channel, voltage-gated,&\\
     && type X, alpha subunit & 0.604 \\
\hline
 35 &  D01799 &  Glyclopyramide & 0.739 \\
   &  hsa3758 &  KCNJ1: potassium inwardly-rectifying&\\
     && channel, subfamily J, member 1 & 0.394 \\
\hline
 36 &  D01599 &  Gliclazide & 0.792 \\
   &  hsa3758 &  KCNJ1: potassium inwardly-rectifying&\\
     && channel, subfamily J, member 1 & 0.394 \\
\hline
 37 &  D01448 &  Trifluoperazine maleate & 0.745 \\
   &  hsa3782 &  KCNN3: potassium intermediate/small&\\
     && conductance calcium-activated channel, subfamily N, member 3 & 0.630 \\
\hline
 38 &  D02356 &  Verapamil & 0.409 \\
   &  hsa3776 &  KCNK2: potassium channel,&\\
     && subfamily K, member 2 & 0.513 \\
\hline
 39 &  D02356 &  Verapamil & 0.122 \\
   &  hsa11280 &  SCN11A: sodium channel, voltage-gated,&\\
     && type XI, alpha subunit & 0.477 \\
\hline
 40 &  D03991 &  Encainide hydrochloride & 0.533 \\
   &  hsa6336 &  SCN10A: sodium channel, voltage-gated,&\\
     && type X, alpha subunit & 0.604 \\
\hline
 41 &  D02356 &  Verapamil & 0.294 \\
   &  hsa6833 &  ABCC8: ATP-binding cassette,&\\
     && sub-family C (CFTR/MRP), member 8 & 0.682 \\
\hline
 42 &  D03991 &  Encainide hydrochloride & 0.533 \\
   &  hsa8645 &  KCNK5: potassium channel,&\\
     && subfamily K, member 5 & 0.013 \\
\hline
 43 &  D00542 &  Halothane & 0.667 \\
   &  hsa3736 &  KCNA1: potassium voltage-gated&\\
     && channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) & 0.049 \\
\hline
 44 &  D02087 &  Moricizine hydrochloride & 0.432 \\
   &  hsa6336 &  SCN10A: sodium channel, voltage-gated,&\\
     && type X, alpha subunit & 0.604 \\
\hline
 45 &  D00536 &  Felbamate & 0.258 \\
   &  hsa8001 &  GLRA3 & 0.833 \\
\hline
 46 &  D02088 &  Tocainide hydrochloride & 0.684 \\
   &  hsa8645 &  KCNK5: potassium channel,&\\
     && subfamily K, member 5 & 0.013 \\
\hline
 47 &  D00228 &  Amoxapine & 0.556 \\
   &  hsa6531 &  SLC6A3: solute carrier family 6&\\
     && (neurotransmitter transporter, dopamine), member 3 & 0.682 \\
\hline
 48 &  D00438 &  Nimodipine & 0.750 \\
   &  hsa773 &  CACNA1A: calcium channel,&\\
     && voltage-dependent, P/Q type, alpha 1A subunit & 0.284 \\
\hline
 49 &  D00638 &  Flecainide acetate & 0.255 \\
   &  hsa3738 &  KCNA3: potassium voltage-gated&\\
     && channel, shaker-related subfamily, member 3 & 0.669 \\
\hline
\bfseries 50 & \bfseries D03365 & \bfseries Nicotine & 0.409 \\
\bfseries\indb{C,D}   & \bfseries hsa1139 & \bfseries CHRNA7: cholinergic receptor,&\\
     &&\bfseries nicotinic, alpha 7 & 0.356 \\
\hline
\end{tabular}
